ImpriMed unveils cancer treatment forecast technology [Video]

ImpriMed, a precision medicine company, announced that it has expanded its services to include human oncology.

The aim is to provide drug-response predictions for routine blood cancers such as newly diagnosed multiple myeloma and acute myeloid leukemia. 

ImpriMed’s human precision medicine services will set their sights on complex blood cancers via a combination of genomic analysis, ex vivo drug sensitivity testing and machine learning.

Data from the company’s new research for naive non-Hodgkin lymphoma treatment outcomes will be presented at the EHA-SfPM meeting in Copenhagen, Denmark, September 25-27.

“The expansion of ImpriMed’s precision medicine services from veterinary to human oncology is a pivotal milestone in our mission to transform cancer treatment,” Dr. Sungwon Lim, ImpriMed chief executive officer, said in a statement.

“By empowering oncologists and researchers to leverage AI-driven technology to predict treatment outcomes, every patient can receive truly personalized therapy. With our expansion into contract research organization services, we look forward to supporting the development …